Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Company and personnel

28 February 2023

GenSight Biologics Announces its 2023 Financial Calendar

04 January 2023

GenSight Biologics to Present at Upcoming Investor Conferences

23 December 2022

GenSight Biologics secures €12 Million financing through a premium convertible notes issuance to an institutional investor and provides business update

04 November 2022

GenSight Biologics secures a €35 million credit facility from the European Investment Bank to support the launch of LUMEVOQ® in Europe

20 September 2022

GenSight Biologics to Present at Upcoming Industry and Investor Conferences

12 September 2022

GenSight Biologics strengthens its management team to support the launch of LUMEVOQ® in Europe

28 July 2022

GenSight Biologics Reports Interim Financial Results for the First Half of 2022

28 Oct 2021 - 29 Oct 2021

Cell UK by Oxford’s Global, London (UK) & Virtual

25 Oct 2021 - 28 Oct 2021

BIO-Europe 2021, Virtual

12 October 2021

GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 15
  • View next 9 articles
© 2023 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page